{"analyses":[{"ciLowerLimit":"-6.4","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.4","estimateComment":"Difference in percentages calculated as % Women 27-45 Years of Age minus % Women 16-26 Years of Age.","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.212","paramType":"Difference in Percentages","paramValue":"-2.5","statisticalMethod":"Miettinen & Nurminen"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.2"},{"groupId":"OG001","value":"84.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"570"},{"groupId":"OG001","value":"640"}],"units":"Participants"}],"description":"Participants were asked to record any injection-site reactions prompted in the Vaccination Report Card, i.e., injection-site tenderness, swelling, or redness, occurring after each study vaccination (solicited injection-site reactions). The percentage of participants with 1 or more solicited injection-site AE was assessed.","groups":[{"description":"Young adult women 16- to 26-years old received V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.","id":"OG000","title":"Women 16-26 Years of Age"},{"description":"Adult women 27- to 45-years old received V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.","id":"OG001","title":"Women 27-45 Years of Age"}],"paramType":"NUMBER","populationDescription":"All participants that received at least 1 vaccination and had available data for endpoint.","reportingStatus":"POSTED","timeFrame":"Up to 5 days post any vaccination","title":"Percentage of Participants With at Least 1 Solicited Injection-site Adverse Event","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}